Expertise in
5
conditions

Dr. Kelvin B. Raybon

Hematology
VCU Health Massey Pharmacy
1001 E Leigh St, 
Richmond, VA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
5
conditions
VCU Health Massey Pharmacy
1001 E Leigh St, 
Richmond, VA 

Overview

Kelvin Raybon is a Hematologist practicing medicine in Richmond, Virginia.

Dr. Raybon is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, and Follicular Lymphoma.

He is actively involved in clinical research, participating in 25 clinical trials. Dr. Raybon is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MS

Hospital Affiliations

Augusta Health

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthKeepers
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Piedmont
  • HMO
  • POS
Sentara Healthcare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

VCU Health Massey Pharmacy
1001 E Leigh St, Richmond, VA 23298

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
View 9 Less Clinical Trials
Similar Doctors
Expertise in
35
conditions
Expertise in
35
conditions
Referral may be required

Office

1001 E Leigh St Fl 4, 
Richmond, VA 
 (0.1 miles away)
804-828-7929
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

John Barrett is a Hematologist practicing medicine in Richmond, Virginia. Dr. Barrett is highly rated in 35 conditions, according to our data. His clinical expertise encompasses Hemophilia A, Hemophilia B, Hemophilic Arthropathy, Chronic Myelogenous Leukemia (CML), and Bone Marrow Aspiration. Dr. Barrett is currently accepting new patients.

Expertise in
30
conditions
Dr. Sosipatros A. Boikos
Hematology | Oncology
Expertise in
30
conditions
Dr. Sosipatros A. Boikos
Hematology | Oncology
Referral may be required

Virginia Commonwealth University Health System Authority

1250 E Marshall St, 
Richmond, VA 
 (1.9 miles away)
804-828-7999
Languages Spoken:
English, Greek
See accepted insurances
Accepting New Patients

Sosipatros Boikos is a Hematologist and an Oncologist practicing medicine in Richmond, Virginia. Dr. Boikos is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Synovial Sarcoma, Gastrointestinal Stromal Tumor, Adult Soft Tissue Sarcoma, Neuroendocrine Tumor, and Bone Marrow Aspiration. Dr. Boikos is currently accepting new patients.

Expertise in
59
conditions
Dr. James L. Khatcheressian
Hematology | Hematology Oncology
Expertise in
59
conditions
Dr. James L. Khatcheressian
Hematology | Hematology Oncology
Referral may be required

Virginia Cancer Institute - West End

8007 Discovery Drive, Suite A, 
Richmond, VA 
 (5.9 miles away)
804-287-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Khatcheressian is a Hematologist and a Hematologist Oncology provider practicing medicine in Richmond, Virginia. Dr. Khatcheressian is highly rated in 59 conditions, according to our data. His clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Khatcheressian is board certified in (Internal Medicine, Medical Oncology) and American Board Of Internal Medicine. Dr. Khatcheressian is currently accepting new patients.

Frequently Asked Questions about Dr. Kelvin B. Raybon

How do I make an appointment with Dr. Kelvin B. Raybon?

You can book an appointment with Dr. Kelvin B. Raybon by calling their office at 804-828-7999. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kelvin B. Raybon a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kelvin B. Raybon is classified as an Advanced expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kelvin B. Raybon specialize in?

While Dr. Kelvin B. Raybon is a Hematology, they have specific expertise in Hodgkin Lymphoma, Muscle Invasive Bladder Cancer, and Non-Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Kelvin B. Raybon accept my insurance?

Dr. Kelvin B. Raybon accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 804-828-7999 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Raybon's expertise for a condition
ConditionClose
      View All 42 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile